Antibacterials: Products and markets
Market Analysis
Product Analysis
The world market for antibacterials in 1999 was $4.9 billion, accounting for 27% of the global animal health and nutrition sector. The market is undergoing a significant period of consolidation, although a large number of smaller generic producers are influential in a wide range of product sectors.
Animal Pharm Reports provides you with a review of the changing nature of the antibacterials market. Antibacterials: Products and markets features detailed national and product market sizes. It will enable you to access up-to-date information on the trends, products and key companies in each country and product sector.
Antibacterials: Products and markets allows you to:
PUBLISHED: DECEMBER 2000
REFERENCE: SR197E
PRICE: £395/$830/¥95,000
PAGES: 140
For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]
CONTENTS
LIST OF TABLES
EXECUTIVE SUMMARY
ABBREVIATIONS
CHAPTER 1 - COMMERCIALLY SIGNIFICANT BACTERIAL INFECTIONS (34 pages)
1.1 Introduction
1.2 Commercially significant bacterial infections in the pig
1.2.1 Major alimentary tract infections of the pig
1.2.1.1 Escherichia coli infections
1.2.1.2 Salmonellosis
1.2.1.3 Porcine proliferative enteropathy (PPE or ileitis)
1.2.1.4 Spirochaetal infections of the pig
1.2.1.5 Incidence of enteric diseases reported in pigs
1.2.2 Major respiratory tract infections of the pig
1.2.2.1 Enzootic pneumonia and mycoplasma-induced respiratory disease (MIRD) complex
1.2.2.2 Atrophic rhinitis
1.2.2.3 Actinobacillus pleuropneumoniae
1.2.2.4 Gl�sser's disease
1.2.2.5 Incidence of respiratory diseases reported in pigs
1.2.3 Streptococcal disease
1.2.3.1 Streptococcal meningitis
1.3 Commercially significant bacterial infections in poultry
1.3.1 Systemic and respiratory infections of poultry
1.3.1.1 Escherichia coli infections
1.3.1.2 Salmonellosis
1.3.1.3 Pasteurellosis (fowl cholera)
1.3.1.4 Riemerella (Pasteurella) anatipestifer infection
1.3.1.5 Infectious Coryza (Haemophilus paragallinarum)
1.3.1.6 Erysipelas (Erysipelothrix rhusiopathiae)
1.3.1.7 Mycoplasmal infections
1.3.2 Enteric infections of poultry
1.3.2.1 Necrotic enteritis (Clostridium perfringens type C)
1.3.2.2 Avian intestinal spirochaetosis
1.3.3 Incidents of diseases reported in poultry
1.4 Commercially significant bacterial infections in cattle
1.4.1 Major enteric bacterial infections in cattle
1.4.1.1 Escherichia coli infections
1.4.1.2 Salmonella infections
1.4.2 Bovine respiratory diseases
1.4.3 Feedlot cattle
1.4.4 Bovine mastitis
1.4.4.1 Contagious mastitis
1.4.4.2 Environmental mastitis
1.4.4.3 Incidence and effects of mastitis
1.4.4.4 Treatment of mastitis
1.4.4.5 Bacterial incidence
1.5 Commercially significant bacterial infections in sheep
1.6 Commercially significant bacterial infections in fish
1.6.1 Gram-negative gliding bacteria (Flavobacteriaceae)
1.6.2 Gram-negative rods (Enterobacteriaceae)
1.6.3 Gram-negative rods (Pasteurellaceae)
1.6.4 Gram-negative vibrio (Vibrionaceae)
1.6.5 Gram-positive aerobic rods (various families)
1.6.6 Gram-positive cocci
1.6.7 Gram-positive anaerobic rods
1.6.8 Obligate intracellular parasites (rickettsia and chlamydia)
1.7 Commercially significant bacterial infections in horses
1.8 Commercially significant bacterial infections in small animals/companion animals
1.8.1 Alimentary tract
1.8.2 Respiratory system
1.8.3 Urinary and reproductive tracts
1.8.4 Skin
1.8.5 Otitis externa
1.8.6 Eye infections
1.8.7 Post-surgical antibacterial use
CHAPTER 2 - ANTIBACTERIAL PRODUCTS (26 pages)
2.1 Introduction
2.2 Beta-lactam antibacterials: penicillins, synthetic penicillins, cephalosporins, macrolides
2.2.1 Mode of action
2.2.2 Penam penicillins
2.2.2.1 Group 1: Narrow spectrum penicillins
2.2.2.2 Group 2: Penicillinase-stable penicillins
2.2.2.3 Group 3: Broader-spectrum penicillins
2.2.2.4 Group 4: Anti-Pseudomonas penicillins
2.2.3 Cephalosporins
2.2.3.1 First generation cephalosporins
2.2.3.2 Second generation cephalosporins
2.2.3.3 Third generation cephalosporins
2.2.3.4 Fourth generation cephalosporins
2.2.4 Monobactams
2.2.5 Anti-mastitis products
2.3 Aminoglycosides and aminocyclitols
2.3.1 Mode of action
2.3.2 Product summaries
2.3.2.1 Streptomycin and dihydrostreptomycin
2.3.2.2 Neomycin (and framycetin)
2.3.2.3 Kanamycin group
2.3.2.4 Aminocyclitol (spectinomycin)
2.4 Polymixins
2.5 Sulphonamides and trimethoprim combinations
2.5.1 Mode of action and uses
2.5.2 Diaminopyrimidines: trimethoprim, ormetoprim and baquiloprim
2.5.2.1 Mode of action and uses
2.6 Chloramphenicol, thiamphenicol and florfenicol
2.6.1 Mode of action
2.6.2 Thiamphenicol and florfenicol
2.7 Tetracyclines: tetracycline, chlortetracycline, oxytetracycline, doxycycline, minocycline
2.7.1 Mode of action and uses
2.8 Fluoroquinolones
2.8.1 Mode of action and uses
2.9 Macrolides, lincosamides and pleuromutilins
2.9.1 Macrolides: tylosin, tilmicosin, aivlosin, erythromycin, azitromycin, spiramycin, josamycin, kitasamycin
2.9.2 Lincosamides: lincomycin, clindamycin
2.9.3 Pleuromutilins: tiamulin, valnemulin
2.9.3.1 Mode of action and uses
2.10 Growth promoters
CHAPTER 3 - ANTIBACTERIAL MARKET SIZES (30 pages)
3.1 Introduction to the global market
3.2 National antibacterial market sizes
3.3 Europe
3.3.1 France
3.3.1.1 Animal numbers
3.3.1.2 Antibacterial sales
3.3.2 Germany
3.3.2.1 Animal numbers
3.3.2.2 Antibacterial sales
3.3.3 Spain
3.3.3.1 Animal numbers
3.3.3.2 Antibacterial sales
3.3.4 UK
3.3.4.1 Animal numbers
3.3.4.2 Antibacterial sales
3.4 North America
3.4.1 Canada
3.4.1.1 Animal numbers
3.4.2 US
3.4.2.1 Animal numbers
3.4.2.2 Antibacterial sales
3.5 South America
3.5.1 Argentina
3.5.1.1 Animal numbers
3.5.1.2 Antibacterial sales
3.5.2 Brazil
3.5.2.1 Animal numbers
3.5.3 Mexico
3.5.3.1 Animal numbers
3.6 Australasia and Asia
3.6.1 Australia
3.6.1.1 Animal numbers
3.6.1.2 Antibacterial sales
3.6.2 China
3.6.2.1 Animal numbers
3.6.2.2 Antibacterial sales
3.6.3 India
3.6.3.1 Animal numbers
3.6.3.2 Antibacterial sales
3.6.4 Japan
3.6.4.1 Animal numbers
3.6.4.2 Antibacterial sales
3.6.5 South Korea
3.6.5.1 Animal numbers
3.7 Market sector by species
3.7.1 The pig market
3.7.2 The poultry market
3.7.2.1 The turkey and duck markets
3.7.3 The cattle market
3.7.3.1 Mastitis
3.7.3.2 Dairy cattle
3.7.3.3 Beef cattle
3.7.3.4 US cattle feedlot market
3.7.4 Companion animals
CHAPTER 4 - COMPANY PROFILES (34 pages)
4.1 Introduction
4.2 Alpharma
4.2.1 Company background
4.2.2 Antibacterial products
4.3 Bayer Animal Health
4.3.1 Company background
4.3.2 Antibacterial products
4.4 Boehringer Ingelheim
4.4.1 Company background
4.4.2 Antibacterial products
4.5 Ceva Sant� Animale (formerly Sanofi)
4.5.1 Company background
4.5.2 Antibacterial products
4.6 Elanco
4.6.1 Company background
4.6.2 Antibacterial products
4.6.2.1 Tylosin
4.6.2.2 Monensin
4.6.2.3 Tilmicosin
4.6.2.4 Others
4.7 Fort Dodge (American Home Products)
4.7.1 Company background
4.7.2 Antibacterial products
4.8 Intervet (Akzo Nobel)
4.8.1 Company background
4.8.2 Antibacterial products
4.9 Merial
4.9.1 Company background
4.9.2 Antibacterial products
4.10 Novartis Animal Health
4.10.1 Company background
4.10.2 Antibacterial products
4.11 Phibro Animal Health
4.11.1 Company background
4.11.2 Antibacterial products
4.12 Pfizer Animal Health
4.12.1 Company background
4.12.2 Antibacterial products
4.13 Pharmacia Corp
4.13.1 Company background
4.13.2 Antibacterial products
4.13.2.1 Ceftiofur
4.13.2.2 Lincomycin and spectinomycin
4.13.2.3 Others
4.14 Schering-Plough
4.14.1 Company background
4.13.2 Antibacterial products
REFERENCES
FURTHER READING
EXECUTIVE SUMMARY
The world animal health and nutrition market was worth $18.4 billion in 1999. The world market for antibacterials accounted for 27% of this, equivalent to $4.9 billion. This represents a decline of 3.2% on the 1998 figure.
The antibacterials market is classified into pharmaceutical products and those that are applied in livestock feed. The former are applied to treat infections; sales rose 12% in 1999 to reach $2,74 billion. In-feed antibacterials are further classified into therapeutics (ie to treat or prevent diseases), growth promoters, and anticoccidials (which are largely used for poultry). In-feed antibacterial sales fell by 17% to reach $2.19 billion in 1999, due to restrictions on the use of growth promoters and the poor market conditions in the global pig industry. The restrictions on the use of growth promoters is part of reason for the growth in the use of pharmaceutical antibacterials, as farmers switched from a prophylactic to a therapeutic approach, ie treating diseases as they occur.
The US is the largest national market for antibacterials, with sales of $1.3 billion in 1999. China is the second largest market, and is worth $250-350 million, although reliable statistics are not available. Antibacterial sales in Japan were $222 million in 1999. In Europe, the largest markets are France ($252 million), Germany ($172 million) and Spain ($167 million). This report presents detailed market size information, including a breakdown of sales in each major market by delivery method.
In terms of species, pigs and poultry each account for one-third of global sales, followed by cattle with 24%. The companion animal market was worth just $250 million in 1999, but represents good long-term growth prospects, especially in North America, Western Europe and Japan. The report presents breakdowns for the major species markets.
The industry is undergoing significant consolidation. Since mid-1999, Novartis has acquired Vericore, Intervet has bought Hoechst Roussel's animal health operations, Alpharma has acquired Roche's animal feeds additives operations, and Pfizer has sold its antibacterial feed additive business to Phibro. Elanco is now the largest supplier of antibacterials, with estimated sales of $595 million in 1999. When the most recent rounds of acquisitions have been consolidated, second place will be contested by Phibro and Alpharma, with sales of around $370 million each. The best-selling antibacterials are oxytetracycline (first developed by Pfizer) and tylosin (Elanco). Both are off-patent and available in many generic forms.
The industry is challenged by continuing moves to ban antibacterials or restrict their use due to concerns about resistance problems. However, they remain essential to intensive livestock production and continue to offer good returns to innovative low cost producers.
NB. Throughout this report, anticoccidials have been included with antibacterials.
© PJB Publications Ltd. 2000 All rights reserved. |